How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,464 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Janus Kinase 1 in Vitiligo & Psoriasis

Janus Kinase 1 in Vitiligo & Psoriasis Janus Kinase 1 in Vitiligo & Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Janus Kinase 1 in Vitiligo & Psoriasis The safety and scientific validity (...) of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases. Condition or disease Intervention/treatment Phase Vitiligo Other: skin biopsy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Other Official

2018 Clinical Trials

182. Molecular and cellular basis of depigmentation in vitiligo patients. Full Text available with Trip Pro

Molecular and cellular basis of depigmentation in vitiligo patients. Vitiligo is a chronic skin disease characterized by the appearance of zones of depigmentation. It is mostly described as an autoimmune disease in which the immune system destroys the melanocytes. Consistent with this origin, genetic studies have implicated genes encoding proteins mediating the immune response targeting melanocytes in the aetiology of this disease, together with proteins specific to these cells. However (...) , the destruction of melanocytes by the immune system is neither global nor complete, because the patients do not display total depigmentation. The etiopathology of vitiligo is clearly complex and cannot be simply reduced to an autoimmune reaction directed against pigmented cells. Intrinsic changes have been observed in the melanocytes, keratinocytes and dermal cells of vitiligo patients. Identification of the molecular and cellular changes occurring in normally pigmented skin in vitiligo patients

2018 Experimental Dermatology

183. Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases. (Abstract)

Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases. Peripheral blood skin-homing/cutaneous lymphocyte antigen (CLA)+ T cells emerge as biomarkers of cutaneous immune activation in patients with inflammatory skin diseases (atopic dermatitis [AD] and alopecia areata [AA]). However, blood phenotyping across these subsets is not yet available in patients with vitiligo.We sought to measure cytokine production by circulating skin-homing (CLA (...) +) versus systemic (CLA-) "polar" CD4+/CD8+ ratio and activated T-cell subsets in patients with vitiligo compared with patients with AA, AD, or psoriasis and control subjects.Flow cytometry was used to measure levels of the cytokines IFN-γ, IL-13, IL-9, IL-17, and IL-22 in CD4+/CD8+ T cells in the blood of 19 patients with moderate-to-severe nonsegmental/generalized vitiligo, moderate-to-severe AA (n = 32), psoriasis (n = 24), or AD (n = 43) and control subjects (n = 30). Unsupervised clustering

2018 Journal of Allergy and Clinical Immunology

184. Plasma & urinary catecholamines & urinary vanillylmandelic acid levels in patients with generalized vitiligo Full Text available with Trip Pro

Plasma & urinary catecholamines & urinary vanillylmandelic acid levels in patients with generalized vitiligo Vitiligo is an acquired skin disease characterized by depigmented areas of the skin. Increased release of catecholamines from autonomic nerve endings in microenvironment of melanocytes in affected skin might be involved in the aetiopathogenesis of vitiligo. Levels of catecholamines are considered as being related to onset or worsening of the disease. Therefore, in this study, the role (...) of catecholamines was evaluated in mapping disease stability and outcome of vitiligo patients undergoing melanocyte transfer.In this study, circulatory and urinary levels of catecholamine (CA) and vanillylmandelic acid (VMA) were determined in 45 individuals (30 vitiligo patients and 15 healthy controls) using ELISA.A significant increase for plasma and urinary catecholamines along with VMA was observed as compared to healthy controls. When the pre- and post-intervention levels were analyzed in responders

2018 The Indian journal of medical research

185. Use of the 532-nm Q-switched neodymium-doped yttrium aluminum garnet laser for the treatment of recalcitrant repigmentation in vitiligo Full Text available with Trip Pro

Use of the 532-nm Q-switched neodymium-doped yttrium aluminum garnet laser for the treatment of recalcitrant repigmentation in vitiligo 30003131 2019 02 26 2352-5126 4 6 2018 Jul JAAD case reports JAAD Case Rep Use of the 532-nm Q-switched neodymium-doped yttrium aluminum garnet laser for the treatment of recalcitrant repigmentation in vitiligo. 612-614 10.1016/j.jdcr.2018.04.010 Modi Krishna K Wayne State University School of Medicine, Detroit, Michigan. Mohammad Tasneem F TF Department

2018 JAAD Case Reports

186. Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream Full Text available with Trip Pro

Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream A 69-year-old man presented with a black irregular patch on his left cheek. Skin biopsy revealed lentigo maligna melanoma in situ. He was treated via partial excision of the melanoma, followed by the application of 5% imiquimod cream every other night for 6 to 8 hours. The patient experienced severe local inflammation accompanied by burning, edema, and erythema, as well as oozing (...) and crusting. The patient discontinued using the imiquimod cream after 15 applications because of the inflammation. Depigmentation was noted in the treated area 3 months after the initiation of treatment with imiquimod cream. Histological examination using Melan-A staining of the depigmented area revealed an absence of melanocytes, which is consistent with vitiligo. The depigmented lesions improved considerably after a 5-year follow-up, and there was no recurrence of melanoma.

2018 Annals of dermatology

187. Potential anti-vitiligo properties of cynarine extracted from Vernonia anthelmintica (L.) Willd Full Text available with Trip Pro

Potential anti-vitiligo properties of cynarine extracted from Vernonia anthelmintica (L.) Willd Vitiligo is a depigmentation disorder of the skin. It is primarily caused by the destruction of melanocytes or obstruction of the melanin synthesis pathway. Melanin is a type of skin pigment that determines skin color. The seeds of Vernonia anthelmintica (L.) Willd (Kaliziri) are used for treating skin diseases including vitiligo in traditional Uyghur medicine. 1,5‑Dicaffeoylquinic acid (1,5‑diCQA (...) induced by 1,5‑diCQA treatment were significantly attenuated by the protein kinase A (PKA) inhibitor H‑89. Intracellular cyclic adenosine monophosphate (cAMP) concentration and phosphorylation of cAMP‑response element binding protein was increased following 1,5‑diCQA treatment. These results indicated that 1,5‑diCQA stimulated melanogenesis via the MAPK and cAMP/PKA signaling pathways in B16 cells, which has potential therapeutic implications for vitiligo.

2018 International journal of molecular medicine

188. Psychosocial effects of vitiligo: a systematic review

Psychosocial effects of vitiligo: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2020 PROSPERO

189. Size ratios in cellular transplantation for vitiligo: a systematic review

Size ratios in cellular transplantation for vitiligo: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

190. Prevalence of family clustering in non segmental vitiligo

Prevalence of family clustering in non segmental vitiligo Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2020 PROSPERO

191. The efficacy of medications, phototherapy and surgical techniques in treatment of nonsegmental vitiligo: a systematic review and network meta-analysis

The efficacy of medications, phototherapy and surgical techniques in treatment of nonsegmental vitiligo: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

192. Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). (Abstract)

Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). The Vitiligo Extent Score (VES) has recently been introduced as a physicians' score for the clinical assessment of the extent of vitiligo, but a good patient self-assessment score is lacking.The objective is to develop and validate a simplified version of the VES as a patient-reported outcome measure (PROM).After extensive pilot testing, patients were asked to score (...) their vitiligo extent twice with an interval of 2 weeks using the Self Assessment Vitiligo Extent Score (SA-VES). The scores were compared with the physicians' evaluation (VES).The SA-VES demonstrated very good test-retest reliability (intraclass correlation = 0.948, 95% confidence interval [CI]: 0.911-0.970) that was not affected by age, skin type, or vitiligo distribution pattern. According to patients, this evaluation method was easy to use (22% very easy; 49% easy; 29% normal) and required <5 minutes

2016 Journal of American Academy of Dermatology

193. Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo. (Abstract)

Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo. Vitiligo is a skin disorder characterized by loss of melanocytes from the epidermis. A recent study reported that CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, but there is very limited clinical data regarding this issue and little is known about the dynamic changes or correlations with disease severity (...) of these chemokines throughout the disease course.To present clinical data that supports and identifies the pathway of CXCR3 and its ligands in T-lymphocytic cell recruitment in vitiligo.Cytometric bead array, flow cytometry, quantitative real-time polymerase chain reaction and immunohistology were used to examine their systemic and local expression in 80 patients with vitiligo and 40 controls.We showed that serum CXCL9 and CXCL10 were significantly elevated in patients with vitiligo and were higher in patients

2016 British Journal of Dermatology

194. Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. (Abstract)

Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. The association of vitiligo with the HLA complex has been previously described in various populations worldwide. However, until now, no similar study has been conducted in Brazil. The aim of this study was to determine the association of HLA alleles with vitiligo in the population of southeast Brazil.DNA samples from 116 patients with vitiligo (...) = 0.3120, OR = 22.43, 95% CI = 1.12-449.46) and HLA-DQB1*06 (P = 0.0207, Pc = 0.1035, OR = 0.28, 95% CI = 0.10-0.81) were associated with both localized and generalized vitiligo. The haplotype analysis revealed that A*02-B*51-C*15-DRB1*07-DQB1*02 (P = 0.0113), A*02-B*15-C*07-DRB1*13-DQB1*06 (P = 0.0340), and A*29-B*44-C*16-DRB1*07-DQB1*02 (P = 0.0340) were associated with a predisposition to the disease.Our results show that HLA alleles and haplotypes may contribute to the pathogenesis of vitiligo

2016 International Journal of Dermatology

195. Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci Full Text available with Trip Pro

Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci Vitiligo is an autoimmune disease with a strong genetic component, characterized by areas of depigmented skin resulting from loss of epidermal melanocytes. Genetic factors are known to play key roles in vitiligo through discoveries in association studies and family studies. Previously, vitiligo susceptibility genes were mainly revealed through linkage analysis and candidate gene studies (...) . Recently, our understanding of the genetic basis of vitiligo has been rapidly advancing through genome-wide association study (GWAS). More than 40 robust susceptible loci have been identified and confirmed to be associated with vitiligo by using GWAS. Most of these associated genes participate in important pathways involved in the pathogenesis of vitiligo. Many susceptible loci with unknown functions in the pathogenesis of vitiligo have also been identified, indicating that additional molecular

2016 Frontiers in genetics

196. Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL) Full Text available with Trip Pro

Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL) Vitiligo is a multi-factorial pigmentary skin disorder. Recently, the importance of emotional and psychological issues is proposed in incidence, progression, relapse and remission of vitiligo. There are limited studies conducted in developing countries, which assess life quality of patients with vitiligo. The aim of this study was the application and evaluation of a disease (...) -specific quality of life index in Iranian patients, for the first time.This cross-sectional biphasic study was conducted on 25 patients as a pilot and another 173 patients as the main study group, in Razi Hospital, Tehran, Iran, 2013-2014. Persian version of Vitiligo Quality of Life index (VitiQoL) was developed with backward-forward method. Based on the pilot study, the validity and reliability were assessed. The Vitiligo Area and Score Index (VASI), VitiQoL, and their relationship, demographic

2016 Health and quality of life outcomes

197. The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. (Abstract)

The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. Vitiligo is a common acquired depigmentation skin disease characterized by loss or dysfunction of melanocytes within the skin lesion, but its pathologenesis is far from lucid. The gene expression profiling of segmental vitiligo (SV) and generalized vitiligo (GV) need further investigation.To better understanding the common and distinct factors, especially in the view of gene (...) expression profile, which were involved in the diseases development and maintenance of segmental vitiligo (SV) and generalized vitiligo (GV).Peripheral bloods were collected from SV, GV and healthy individual (HI), followed by leukocytes separation and total RNA extraction. The high-throughput whole genome expression microarrays were used to assay the gene expression profiles between HI, SV and GV. Bioinformatics tools were employed to annotated the biological function of differently expressed genes

2016 Journal of dermatological science

198. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. (Abstract)

New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported.To describe the clinical characteristics and evolution of patients developing new-onset vitiligo following initiation of a biological agent for chronic inflammatory disease; and also to report the clinical course of pre-existing (...) vitiligo under biological therapy.This nationwide multicentre, retrospective study, carried out between July 2013 and January 2015, describes the characteristics of a large series of 18 patients (psoriasis N = 8, inflammatory rheumatic diseases N = 8, ulcerative colitis N = 1, uveitis N = 1) who developed new-onset vitiligo while receiving a biological agent.TNFα inhibitors were the most common biological agent involved (13/18) while anti-IL-12/23 and anti-IL-17 agents or abatacept were less common (4

2016 Journal of the European Academy of Dermatology and Venereology

199. Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre. (Abstract)

Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre. 27273338 2017 05 18 2018 12 02 1365-2133 176 2 2017 02 The British journal of dermatology Br. J. Dermatol. Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. 503-506 10.1111/bjd.14790 Teulings H E HE Department of Dermatology and the Netherlands Institute for Pigment Disorders (SNIP), Academic Medical Center (...) Dermatol Ges. 2008 Dec;6(12):1053-9 18479500 Humans Hypopigmentation Melanoma Research Design Retrospective Studies Skin Neoplasms Vitiligo 2016 6 9 6 0 2017 5 19 6 0 2016 6 9 6 0 ppublish 27273338 10.1111/bjd.14790

2016 British Journal of Dermatology

200. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2. Full Text available with Trip Pro

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2. We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses' Health Study 2. We used logistic regression to calculate age- and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were (...) included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow-up. AD was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18-2.76) and vitiligo (OR 2.14, 95% CI 1.29-3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood.© 2017 John Wiley & Sons A/S. Published

2017 Allergy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>